Eli Lilly's Weight-Loss Drugs Drive 65% of Q1 Revenue, But Pricing Headwinds Persist

What happened

Eli Lilly reported Q1 2026 revenue of $19.8 billion, with Mounjaro and Zepbound combined for $12.8 billion, representing 65% of total revenue and underscoring the company's dependence on incretin therapies. Mounjaro revenue surged 125% year over year, but consolidated pricing was a 13% headwind, and the 10-Q noted that these results benefited from favorable one-time rebate adjustments. The stock trades at 42.9x P/E, pricing in sustained growth, yet the DeepValue report rates it a WAIT with no margin of safety due to the risk that gross-to-net erosion becomes structural. Key upcoming catalysts include the Medicare GLP-1 Bridge (July 2026) and CVS Caremark Zepbound coverage (October 2026), which may boost volume but could also further pressure realized prices. Early Foundayo oral prescription data show modest uptake, and the thesis hinges on whether volume growth can outpace persistent discounting in the coming quarters.

Implication

Lilly's incretin franchise is generating enormous volume growth, but the net pricing headwind of 13% and the reliance on one-time adjustments mean that earnings quality is weaker than top-line growth suggests. Investors should monitor upcoming quarterly disclosures for trends in realized price and Foundayo uptake; a sustained improvement in pricing could warrant adding to positions, while further deterioration would confirm the risk of a structural compression. Given the crowded trade and elevated multiples, patience is prudent.

Thesis delta

The report's WAIT rating remains appropriate as the news confirms strong volume but does not resolve the central concern that net pricing pressures could compress margins. The key variable is whether the upcoming access expansions (Medicare Bridge, PBM coverage) translate into volume that offsets discounting, or if they exacerbate the price headwind. Until that is observable, the stock offers poor risk/reward.